| pimecrolimus topical / Generic mfg. |
2006-000336-28: A 52-week open-label, single-arm, multi-center study to evaluate the long term safety of pimecrolimus 1% cream intermittent treatment of seborrhoeic dermatitis in patients 12 years of age and older |
|
|
| Ongoing | 4 | 544 | Europe | Elidel Cream 1%, Cream, Elidel, creme | Novartis Pharma Services AG | Seborrhoeic dermatitis (SD) | | | | |
ChiCTR2200060584: A randomized controlled study comparing the efficacy and safety of 2% Crisaborole ointment versus 1% Pimemollimus cream in the treatment of mild to moderate atopic dermatitis in children aged 2 years and older |
|
|
| Recruiting | 4 | 120 | | Topical use of Crisaborole, twice a day ;Topical use of Pimecrolimus, twice a day | Shenzhen Children's Hospital; Shenzhen Children's Hospital, Chinese National Health Association | Atopic dermatitis | | | | |
2005-006208-21: Clinical Efficacy of Pimecrolimus Cream in Seborrheic Dermatitis. Efficacy of pimecrolimus in normalizing clinical symptoms, explorative study of barrier function, hydration, lipid content and differentiation in seborrheic dermatitis: a randomized, double-blind study in adults with seborrheic dermatitis treated with 1 % pimecrolimus cream versus 2 % ketoconazole cream as control. |
|
|
| Ongoing | 3 | 32 | Europe | elidel 1% cream, Nizoral 2% cream, elidel 1% cream, Nizoral 2% cream | Department of Dermatology, University of Kiel | Efficacy of pimecrolimus in normalizing clinical symptoms, explorative study of barrier function, hydration, lipid content and differentiation in seborrheic dermatitis | | | | |
AQUA, NCT06241118: A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor |
|
|
| Recruiting | 3 | 249 | Europe, Canada, Japan, US, RoW | Amlitelimab, SAR445229, Placebo, Topical corticosteroids, Topical tacrolimus or pimecrolimus | Sanofi | Dermatitis Atopic | 03/26 | 06/26 | | |
2007-003106-99: Pimecrolimus and Epidermal Barrier Function: Role for pimecrolimus in restoring skin barrier function and normalizing epidermal lipid content and differentiation in atopic epidermis: a randomized, intra-patient, double-blind (right/left arm) study in adults with atopic dermatitis treated with 1% pimecrolimus cream and 0.1% triamcinolone acetonide cream as treatment control twice daily for 3 weeks |
|
|
| Ongoing | 2 | 15 | Europe | elidel 1 % cream, Triamgalen 0.1 % cream, elidel 1 % cream, Triamgalen 0.1 % cream | University of Kiel, Department of Dermatology | Investigative study of pathogenesis/treatment of calcineurin inhibitor vs. corticosteroid confirmatory study to prior study: Pimecrolimus and Epidermal Barrier Function, Protocol No. ELBE-2005, EudraCT No.: 2004-004824-11 | | | | |
NCT05729074: A Study to Evaluate the Safety, Tolerability and Pharmacokinetic Properties of IN-A002 Ointment in Healthy Adult Male Volunteers and Mild to Moderate Atopic Dermatitis Patients |
|
|
| Not yet recruiting | 1 | 80 | NA | IN-A002 Ointment 0.3% or IN-A002 Placebo Ointment, IN-A002 Ointment 0.5% or IN-A002 Placebo Ointment, IN-A002 Ointment 1% or IN-A002 Placebo Ointment, IN-A002 Ointment 3% or IN-A002 Placebo Ointment, IN-A002 Ointment 5% or IN-A002 Placebo Ointment, IN-A002 Ointment 1%, IN-A002 Ointment 3%, Elidel Cream 1% (pimecrolimus) | HK inno.N Corporation | Mild to Moderate Atopic Dermatitis | 02/23 | 01/24 | | |
ChiCTR-IOR-17013549: Anti-microbial, anti-inflammatory treatment of seborrheic dermatitis with single center, researcher blind, randomized controlled study |
|
|
| Recruiting | N/A | 180 | | Pimecrolimus Cream ;Fusidic acid cream ;LA ROCHE-POSAY TOLERIANE ULTRA | 1st Hospital of China Medical University; 1st Hospital of China Medical University, Science and technology platform | seborrheic dermatitis | | | | |
NCT04976868: Observational Study to Evaluate the Actual Use of Elidel® in Chinese Patients With Mild to Moderate Atopic Dermatitis |
|
|
| Completed | N/A | 130 | RoW | Pimecrolimus 1% Top Cream | Mylan Inc., Medicine Meda Pharmaceutical Information Consultancy (Beijing) Co., Ltd. | Atopic Dermatitis | 10/22 | 10/22 | | |
Elidel-SEA, NCT06052995: Observational Study to Evaluate Use of Elidel® in South and East Asian Pediatric Patients With Atopic Dermatitis. |
|
|
| Not yet recruiting | N/A | 130 | NA | Elidel 1% Topical Cream | MEDA PHARMA SPA, a Viatris company | Mild to Moderate Atopic Dermatitis | 08/24 | 02/25 | | |
